1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to shore up your portfolio's exposure to growth. Assuming you can tolerate the additional risk that comes with trying to do things differently, that is.
In biotech, disruptive companies could be those with unique technology platforms with uncommon capabilities, or those with programs for medicines that could be unusually effective at their intended purposes. Let's take a look at one of each, with the understanding that only one of the pair is mature enough to be ready to buy for most investors.
Viking Therapeutics (NASDAQ: VKTX) is disruptive because it could have a shot at breaking into the market for obesity medicines, which is currently dominated by Novo Nordisk and Eli Lilly with their medicines Wegovy and Zepbound.
Source Fool.com
